Lantern Pharma Announces Successful Early Completion of LP-300 Phase 2 HARMONIC™ Clinical Trial Enrollment in Japan
Lantern Pharma Inc. has announced the successful completion of targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan, focusing on the treatment of non-small cell lung cancer (NSCLC) in never-smoker patients. The trial is evaluating the efficacy of LP-300 in combination with carboplatin and pemetrexed for patients whose cancer has progressed following treatment with tyrosine kinase inhibitors (TKIs). A total of 10 patients were enrolled ahead of schedule at five clinical sites, including the National Cancer Center Japan. Lantern Pharma is planning to release further clinical and outcome data from this trial later this quarter, which will cover both Asian and U.S. patient cohorts. The trial aims to address the unmet medical needs of this specific patient population.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731092114) on July 31, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。